Healius Limited (ASX:HLS) Announces Half Year Results
Healius Limited (ASX:HLS) reports a 10% revenue increase in 1H25, highlights strong EBIT growth and plans to sell Lumus Imaging.
Category: Healthcare
Healius Limited (ASX:HLS) Releases Independent Auditor’s Review Report
Healius Limited (ASX:HLS) releases an independent auditor’s review confirming compliance with key regulations and accounting standards.
Wellnex Life Limited (ASX:WNX) Secures $14.3M for AIM Dual Listing
Wellnex Life Limited (ASX:WNX) secures $14.3 million for AIM dual listing, supporting debt redemption and acquisition payments.
Sonic Healthcare Limited (ASX:SHL) Reports H1 2024 Results
Sonic Healthcare Limited (ASX:SHL) reports an 8.4% revenue increase and a 17% profit rise in H1 2024, alongside a 2.3% interim dividend hike.
Nanosonics Limited (ASX:NAN) Announces 2025 Half-Year Financial Results
Nanosonics (ASX:NAN) reports an 18% revenue increase in its 2025 half-year, highlighting strong growth and future outlook.
Oakridge International Limited (ASX:OAK) Releases Half-Year Financial Report
Oakridge International Limited (ASX:OAK) reports a 109% revenue increase and a 72% reduction in loss for the half-year ended 31 December 2024.
Beamtree Holdings Limited (ASX:BMT) Announces 1H FY25 Results
Beamtree Holdings Limited (ASX:BMT) reports a 10% revenue increase in 1H FY25 and launches its Integrated Coding Platform in Saudi Arabia.
Imagion Biosystems (ASX:IBX) Starts Manufacturing for Phase 2 HER2+ Breast Cancer Study
Imagion Biosystems (ASX:IBX) commences manufacturing of MagSense® for its Phase 2 HER2+ breast cancer clinical study, advancing its cancer diagnostic platform.
Neuren Pharmaceuticals (ASX:NEU) Receives FDA Fast Track for NNZ-2591 in Pitt Hopkins Syndrome
Neuren Pharmaceuticals (ASX:NEU) gains FDA Fast Track designation for NNZ-2591 to treat Pitt Hopkins syndrome, following successful Phase 2 trial.
IDT Australia Limited (ASX:IDT) Announces Half-Year Financial Results
IDT Australia Limited (ASX:IDT) reports an 83% revenue increase and a 15.8% reduction in loss for the half-year ended December 2024.